Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 3, 1996, Pages 1392-1403

  Merchant, Kalpana M ^a   Gill, Gurnam S ^a   Harris, Douglas W ^a   Huff, Rita M ^a   Eaton, Misty J ^b   Lookingland, Keith ^b   Lutzke, Barry S ^a   Mccall, Robert B ^a   Piercey, Montford F ^a   Schreur, Peggy J K D ^a   Sethy, Vimala H ^a   Smith, Martin W ^a   Svensson, Kjell A ^a   Tang, Andrew H ^c   Vonvoigtlander, Philip F ^a   Tenbrink, Ruth E ^a  

^a PFIZER INC   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AMPHETAMINE; APOMORPHINE; AUTORECEPTOR; CLOZAPINE; CYCLIC AMP; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; GENE PRODUCT; HALOPERIDOL; HISTAMINE RECEPTOR; QUINPIROLE; SEROTONIN RECEPTOR; SONEPIPRAZOLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG TISSUE LEVEL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; LOCOMOTION; MALE; NEUROENDOCRINE SYSTEM; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR AFFINITY;

AMPHETAMINES; ANIMALS; APOMORPHINE; BINDING SITES; BIOLOGICAL AVAILABILITY; BRAIN; CLONING, MOLECULAR; DOPAMINE; DOPAMINE ANTAGONISTS; GENE EXPRESSION REGULATION; GENES, FOS; HUMANS; MALE; MICE; MOTOR ACTIVITY; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; RECOMBINANT PROTEINS; RNA, MESSENGER; SEROTONIN; SULFONAMIDES;

EID: 12644311276     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. BARING, M. D., WALTERS, J. L. AND ENG, N.: Action of systemic apomorphine on dopamine cell firing after neostriatal kainin acid lesion. Brain Res. 181: 214-218, 1980.
2. BOUTHENET, M. L., SOUIL, E., MARTRES, M. P., SOKOLOFF, P. AND SCHWARTZ, J.-C.: Localization of D3 mRNA in the rat brain using in situ hybridization histochemistry: Comparison with dopamine D2 receptor mRNA. Brain Res. 564: 203-219, 1991.
3. BUNNEY, B. S. AND AGHAJANIAN, G. K.: d-Amphetamine-induced inhibition of central dopaminergic neurons: Mediation by a striatonigral feedback pathway. Science 192: 391-393, 1976.
4. BUNNEY, B. S. AND AGHAJANIAN, G. K.: d-Amphetamine-induced depression of central dopamine neurons: evidence for mediation by both, autoreceptors and striatonigral feedback pathway. Naunyn-Schmiedeberg's Arch. Pharmacol. 304: 255-261, 1978.
5. CASTER-RUSSELL, H. R., HONG, W.-J. AND SUBMEIER, D. J.: Coordinated expression of dopamine receptors (D1-D5) in single neostriatal neurons. Abstr. Soc. Neurosci. 21: 1425, 1995.
6. 50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3108, 1973.
7. CHIO, C. L., DRONG, R. F., RILEY, D. T., GILL, G. S., SLIGHTOM, J. L. AND HUFF, R. M.: D4 dopamine receptor-mediated signalling events determined in transfected chinese hamster ovary cells. J. Biol. Chem. 269: 11813-11817, 1994.
8. CIVELLI, O., BUNZOW, J. R. AND GRANDY, D. K: Molecular diversity of the dopamine receptors. Annu. Rev. Pharmacol. Toxicol. 33: 281-307, 1993.
9. DELONG, M. R.: Primate models of movement disorders of basal ganglia circuitry. Trends Neurosci. 13: 280-284, 1990.
10. DEUTCH, A. Y. AND DUMAN, R. S.: The effects of antipsychotic drugs on prefrontal cortical fos expression; cellular localization and pharmacological characterization. Neuroscience 70: 377-389, 1995.
11. DEUTCH, A. Y., MOGHADDAM, B., INNIS, R. B., KRYSTAL, J. H., AGHAJANIAN, G. K., BUNNEY, B. S. AND CHARNEY, D. S.: Mechanisms of actions of atypical antipsychotic drugs: Implications for novel therapeutic strategies of schizophrenia. Schizophr. Res. 4: 121-156, 1991.
12. DEUTCH, A. Y., LEE, M. C. AND IADAROLA, M. J.: Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol. Cell. Neurosci. 3: 332-341, 1992.
13. DIAZ, J., LEVESQUE, D., GRIFFON, N., LAMMERS, C. H., MARTRES, M.-P., SOKOLOFF, P. AND SCHWARTZ, J.-C.: Opposing roles of dopamine D2 and D3 receptors on neurotensin mRNA expression in the nucleus accumbens. Eur. J. Neurosci. 6: 1384-1387, 1994.
14. DRAGUNOW, M., ROBERTSON, G. S., FAULL, R. L. M., ROBERTSON, H. A. AND JANSEN, K.: D2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience 37: 287-292, 1990.
15. A receptor. J. Med. Chem. 35: 3038-3066, 1992.
16. EVA, C., HADJICONSTANTINOU, N., NEFF, N. H. AND MEEK, J. L.: Acetylcholine measurement by high pressure liquid chromatography using an enzyme-loaded post-column reactor. Anal. Biochem. 143: 320-324, 1984.
17. FARDE, L., NORDSTROM, A.-L., WIESEL, F.-A., PAULI, S., HALLDIN, C. AND SEDVALL, G.: Positron emission tomography analysis of central D1 and D2 dopamine receptor occupancy inpatients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 49: 538-544, 1992.
18. FINK-JENSEN, A. AND KRISTENSEN, P.: Effects of typical and atypical neuroleptics on Fos protein expression in rat forebrain. Neurosci. Lett. 182: 115-118, 1994.
19. GIBALDI, M. AND PERRIER, D.: Pharmacokinetics, 2nd ed., pp. 410-414, 445-449, Marcel Dekker, New York, NY, 1982.
20. GOBERT, A., RIVET, J.-M., AUDINOT, V., CISTARELLI, L., SPEDDING, M., VIAN, J., PEGLION, J.-L. AND MILLAN, M. J.: Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and silent D3 autoreceptors control synthesis and release in the mesolimbic, mesocortical and nigrostriatal pathaways. J. Pharmacol. Exp. Ther. 275: 899-913, 1995.
21. GRIFFON, N., DIAZ, J., LEVESQUE, D., SAUTEL, F., SCHWARTZ, J.-C., SOKOLOFF, P., SIMON, P., COSTENTIN, J., GARRIDO, F., MANN, A. AND WERMUTH, C.: Localization, regulation, and role of the dopamine D3 receptor are distinct from those of the D2 receptor. Clin. Neuropharmacol. 18: S130-S142, 1995.
22. GUSTAFSSON, B. AND CHRISTENSSON, E.: Amperozide: A new putatively atypical antipsychotic drug with a limbic mode of action on dopamine mediated behavior. Pharmacol. Toxicol. 1: suppl., 12-17, 1990.
23. KALBFLEISCH, J. D. AND PRENTICE, C. M.: The Statistical Analysis of Failure Time Data, John Wiley & Sons, Inc., New York, 1980.
24. KEBABIAN, J. W. AND CALNE, D. B.: Multiple receptors for dopamine. Nature 277: 93-96, 1979.
25. LANDWEHRMEYER, B., MENGOD, G. AND PALACIOS, J. M.: Differential visualization of dopamine D2 and D3 receptor sites in rat brain, a comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur. J. Neurosci. 5: 145-153, 1993.
26. LAWSON, C. F., MORTIMORE, R. A., SCHLACHTER, S. K. AND SMITH, M. W.: Pharmacology of a human dopamine D4 receptor expressed in HEK293 cells. Methods Find. Exp. Clin. Pharmacol. 16: 303-307, 1994.
27. LOOKINGLAND, K. J. AND MOORE, K. E.: Dopamine receptor mediated regulation of incertohypothalamic dopaminergic neurons in the male rat. Brain Res. 304: 329-338, 1984.
28. MACGIBBON, G. A., LAWLOR, P. A., BRAVO, R. AND DRAGUNOW, M.: Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Mol. Brain Res. 23: 21-28, 1994.
29. MEADOR-WOODRUFF, J. H., MANSOUR, A., SAUL, J. AND WATSON, S. J.: Neuroanatomical distribution of dopamine receptor messenger RNAs. In Dopamine Receptors and Transporters: Pharmacology, Structure, and Function, ed. by H. B. Niznik, pp. 401-414, Marcel Dekker, New York, 1994.
30. MERCHANT, K. M., DOBIE, D. J. AND DORSA, D. M.: Expression of the proneurotensin gene in the rat brain and its regulation by antipsychotic drugs. Ann. NY Acad. Sci. 668: 54-69, 1992.
31. MERCHANT, K. M. AND DORSA, D. M.: Differential induction of neurotensin and c-fos gene expression by typical vs. atypical antipsychotics. Proc. Natl. Acad. Sci. U.S.A. 90: 3447-3451, 1993.
32. MERCHANT, K. M., FIGUR, L. M. AND EVANS, D. L.: Antipsychotic drug-induced expression of c-fos mRNA in the medial prefrontal cortex: Role of D2 versus D3 receptors. Cerebral Cortex 6: 561-570, 1996.
33. MILLAN, M. J., AUDINOT, V., RIVET, J.-M., GOBERT, A., VIAN, J., PROST, F., SPEDDING, M. AND PEGLION, J.-L.: S14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rat. Eur. J. Pharmacol. 260: R3-R5, 1994.
34. MILLAN, M. J., PEGLION, J.-L., VIAN, J., RIVET, J.-M., BROCCO, M., GOBERT, A., NEWMAN-TANCREDI, A., DACQUET, C., BERVOETS, K., GIRARDON, S., JACQUES, V., CHAPUT, C. AND AUDINOT, V.: Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: I. Activation of postsynaptic D3 receptor mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J. Pharmacol. Exp. Ther. 275: 885-898, 1995.
35. NORDSTROM, A., FARDE, L., WIESEL, F., FORSLUND, K., PAULI, S. AND HALLDIN, C.: Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects-a double blind study of schizophrenic patients. Biol. Psychiatry 33: 227-235, 1993.
36. O'MALLEY, K. L., HARMON, S., TANG, L. AND TODD, R. D.: The rat dopamine D4 receptor: Sequence, gene structure and demonstration of expression in the cardiovascular system. New Biologist 4: 137-146, 1992.
37. ÖGREN, S.-O., FLORVALL, L., HALL, H., MAGNUSSON, O. AND ANGEBY-MOLLER, K.: Neuropharmacological and behavioral properties of remoxipride in the rat. Acta Psychiatr. Scand. 82: suppl. 358, 21-26, 1990.
38. ÖGREN, S.-O., HALL, H., KÖHLER, C., MAGNUSSON, O., LINDBOM, L.-O., ANGEBY, K. AND FLORVALL, L.: Remoxipride, a potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur. J. Pharmacol. 102: 459-474, 1984.
39. PAXINOS, G. AND WATSON, C.: The Rat Brain in Stereotaxic Coordinates, Academic Press, San Diego, 1986.
40. PIERCEY, M. F., SMITH, M. W. AND LUM-RAGAN, J. T.: Excitation of noradrenergic cell firing by 5-hydroxytryptamine1A agonists correlates with dopamine antagonist properties. J. Pharmacol. Exp. Ther. 268: 1297-1303, 1994.
41. PROTAIS, P., COSTENTIN, J. AND SCHWARTZ, J.-C.: Climbing behavior induced by apomorphine in mice: A simple test for the study of dopamine receptors in the striatum. Psychopharmacology 50: 1-6, 1976.
42. ROBERTSON, G. S. AND FIBIGER, H. C.: Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine. Neuroscience 46: 315-329, 1992.
43. ROBERTSON, G. S., MATSUMURA, H. AND FIBIGER, H. C.: Induction of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther. 271: 1058-1066, 1994.
44. 3 receptor: Basis and clinical aspects. Clin. Neuropharmacol. 16: 295-314, 1993.
45. SEEMAN, P. AND VAN TOL, H. H. M.: Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15: 264-267, 1994.
46. SETHY, V. H.: Regulation of striatal acetyl choline concentration by D2 dopamine receptors. Eur. J. Pharmacol. 60: 397-398, 1979.
47. SETHY, V. H., ELLERBROCK, B. R. AND WU, H.: Comparative dopaminergic and muscarinic antagonist activity of clozapine and haloperidol. Life Sci. 58: 585-590, 1996.
48. SHUM, A., SOLE, A. J. AND VAN LOON, G. R.: Simultaneous measurement of 5-hydroxytryptophan and 1-dihydroxyphenylalaninine by high performance liquid chromatography with electrochemical detection. Measurement of serotonin and dopamine turnover in discrete brain regions. J. Chromatogr. 228: 123-130, 1982.
49. SONESSON, C., WATERS, N., SVENSSON, K., CARLSSON, A., SMITH, M. W., PIERCEY, M. F., MEIER, E. AND WIKSTROM, H.: Substituted 3-phenylpiperidines: New centrally acting dopamine autoreceptor antagonists. J. Med. Chem. 36: 3188-3196, 1993.
50. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther. 266: 684-691, 1993.
51. SVENSSON, K. A., CARLSSON, A., HUFF, R. M., KLING-PETERSEN, T. AND WATERS, N.: Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur. J. Pharmacol. 263: 235-243, 1994.
52. TENBRINK, R. E., BERGH, C., DUNCAN, J. N., HARRIS, D. W., LAHTI, R. A., LAWSON, C. F., REES, S. A., SCHLACHTER, S. K. AND SMITH, M. W.: S(-)-4-[4-[2-(isochroman-1-yl)ethyl]piperazin-1-yl]benzenesulfonamide, U-101387, a selective dopamine D4 antagonist. J. Med. Chem. 39: 2435-2437, 1996.
53. VAN TOL, H. H. M., BUNZOW, J. R., GUAN, H. C., SUNAHARA, R. K., SEEMAN, P., NIZNIK, H. B. AND CIVELLI, O.: Cloning of the gene for human dopamine D4 receptor with high affinity for the antipsychotic, clozapine. Nature 350: 610-614, 1991.
54. VAN TOL, H. H. M. AND SEEMAN, P.: The dopamine D4 receptor: A novel site for antipsychotic action. Clin. Neuropharmacol. 18: suppl. 1, S143-S153, 1995.
55. VAN TOL, H. H. M., WU, C. M., GUAN, H. C., OHARA, K., BUNZOW, J. R., CIVELLI, O., KENNEDY, J., SEEMAN, P., NIZNIK, H. B. AND JOVANOVIC, V.: Multiple dopamine D4 receptor variants in the human population. Nature 358: 149-152, 1992.
56. WATERS, N., SVENSSON, K. A., HAADSMA-SVENSSON, S. R., SMITH, M. W. AND CARLSSON, A.: The dopamine D3-receptor: A postsynaptic receptor inhibitory on rat locomotor activity. J. Neural. Transm. 94: 11-19, 1993.